Peter Lange

Peter Lange

Auto-generated profile, based on publicly available information

Peter Lange

Medical Department, Copenhagen University Hospital-Herlev, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2012 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
PLPeter Lange
Peter Lange
JMJacob Louis Marott
Jacob Louis Marott
JVJørgen Vestbo
Jørgen Vestbo
KOKim Rose Olsen
Kim Rose Olsen
TITruls Sylvan Ingebrigtsen
Truls Sylvan Ingebrigtsen
BNBørge Grønne Nordestgaard
Børge Grønne Nordestgaard
Rationale: The new Global Initiative for Obstructive Lung Disease (GOLD) stratification of chronic obstructive pulmonary disease (COPD) into categories A, B, C, and D is based on symptoms, level of lung function, and history of exacerbations. Objectives: To investigate the abilities of this stratification to predict the clinical course of COPD. Methods: Two similar population studies were performed in an area of Copenhagen including 6,628 individuals with COPD. Measurements and Main Results: The patients were monitored for an average period of 4.3 years regarding COPD exacerbations, hospital admissions, and mortality. The percentages of individuals experiencing a COPD exacerbation during the first year of observation were 2.2% in group A, 5.8% in group B, 25.1% in group C, and 28.6% in group D. One- and 3-year mortality rates were 0.6 and 3.8%, respectively, in group A, 3.0 and 10.6% in group B, 0.7 and 8.2% in group C, and 3.4 and 20.1% in group D. Groups B and D, characterized by a higher degree of dyspnea than groups A and C, had five to eight times higher mortality from cardiovascular disease and cancer than did groups A and C. Conclusions: The new stratification performs well by identifying individuals at risk of exacerbations. Surprisingly, subgroup B, characterized by more severe dyspnea, had significantly poorer survival than group C, in spite of a higher FEV1 level. This subgroup warrants special attention, as the poor prognosis could be caused by cardiovascular disease or cancer, requiring additional assessment and treatment.

15 June 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
DLDavid A. Lipson
David A. Lipson
CCCourtney Crim
Courtney Crim
GCGerard J. Criner
Gerard J. Criner
NDNicola C. Day
Nicola C. Day
MDMark T. Dransfield
Mark T. Dransfield
OIon behalf of the IMPACT investigators
on behalf of the IMPACT investigators
Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease (COPD) at risk of future exacerbations. Five hundred seventy-four patients were censored in the original analysis owing to incomplete vital status information. Objectives: Report ACM and impact of stepping down therapy, following collection of additional vital status data. Methods: Patients were randomized 2:2:1 to FF/UMEC/VI 100/62.5/25 μg, FF/VI 100/25 μg, or UMEC/VI 62.5/25 μg following a run-in on their COPD therapies. Time to ACM was prespecified. Additional vital status data collection and subsequent analyses were performed post hoc. Measurements and Main Results: We report vital status data for 99.6% of the intention-to-treat population (n = 10,355), documenting 98 (2.36%) deaths on FF/UMEC/VI, 109 (2.64%) on FF/VI, and 66 (3.19%) on UMEC/VI. For FF/UMEC/VI, the hazard ratio for death was 0.72 (95% confidence interval, 0.53–0.99; P = 0.042) versus UMEC/VI and 0.89 (95% confidence interval, 0.67–1.16; P = 0.387) versus FF/VI. Independent adjudication confirmed lower rates of cardiovascular and respiratory death and death associated with the patient’s COPD. Conclusions: In this secondary analysis of an efficacy outcome from the IMPACT trial, once-daily single-inhaler FF/UMEC/VI triple therapy reduced the risk of ACM versus UMEC/VI in patients with symptomatic COPD and a history of exacerbations.

15 September 2018 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
CRCamilla Koch Ryrsø
Camilla Koch Ryrsø
NGNina Skavlan Godtfredsen
Nina Skavlan Godtfredsen
LKLinette Marie Kofod
Linette Marie Kofod
MLMarie Lavesen
Marie Lavesen
LMLine Mogensen
Line Mogensen
UIUlrik Winning Iepsen
Ulrik Winning Iepsen
Pulmonary rehabilitation (PR), delivered as a supervised multidisciplinary program including exercise training, is one of the cornerstones in the chronic obstructive pulmonary disease (COPD) management. We performed a systematic review and meta-analysis to assess the effect on mortality of a supervised early PR program, initiated during or within 4 weeks after hospitalization with an acute exacerbation of COPD compared with usual post-exacerbation care or no PR program. Secondary outcomes were days in hospital, COPD related readmissions, health-related quality of life (HRQoL), exercise capacity (walking distance), activities of daily living (ADL), fall risk and drop-out rate. We identified randomized trials through a systematic search using MEDLINE, EMBASE and Cocharne Library and other sources through October 2017. Risk of bias was assessed regarding randomization, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting, and other biases using the Cochrane Risk of Bias tool. We included 13 randomized trials (801 participants). Our meta-analyses showed a clinically relevant reduction in mortality after early PR (4 trials, 319 patients; RR = 0.58 (95% CI: [0.35 to 0.98])) and at the longest follow-up (3 trials, 127 patients; RR = 0.55 (95% CI: [0.12 to 2.57])). Early PR reduced number of days in hospital by 4.27 days (1 trial, 180 patients; 95% CI: [− 6.85 to − 1.69]) and hospital readmissions (6 trials, 319 patients; RR = 0.47 (95% CI: [0.29 to 0.75])). Moreover, early PR improved HRQoL and walking distance, and did not affect drop-out rate. Several of the trials had unclear risk of bias in regard to the randomization and blinding, for some outcome there was also a lack of power. Moderate quality of evidence showed reductions in mortality, number of days in hospital and number of readmissions after early PR in patients hospitalized with a COPD exacerbation. Long-term effects on mortality were not statistically significant, but improvements in HRQoL and exercise capacity appeared to be maintained for at least 12 months. Therefore, we recommend early supervised PR to patients with COPD-related exacerbations. PR should be initiated during hospital admission or within 4 weeks after hospital discharge.

1 June 2016 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
PLPeter Lange
Peter Lange
YÇYunus Çolak
Yunus Çolak
TITruls Sylvan Ingebrigtsen
Truls Sylvan Ingebrigtsen
JVJørgen Vestbo
Jørgen Vestbo
JMJacob Louis Marott
Jacob Louis Marott

15 October 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JMJacob Louis Marott
Jacob Louis Marott
TITruls Sylvan Ingebrigtsen
Truls Sylvan Ingebrigtsen
YÇYunus Çolak
Yunus Çolak
JVJørgen Vestbo
Jørgen Vestbo
PLPeter Lange
Peter Lange
Rationale: Natural history of preserved ratio impaired spirometry (PRISm), often defined as FEV1/FVC ⩾lower limit of normal and FEV1<80% of predicted value, is not well described. Objectives: To investigate the natural history and long-term prognosis of the following PRISm trajectories: persistent PRISm trajectory (individuals with PRISm both young and middle-aged), normal to PRISm trajectory (individuals developing PRISm from normal spirometry in young adulthood), and PRISm to normal trajectory (individuals recovering from PRISm in young adulthood by normalizing spirometry while middle-aged). Methods: We followed 1,160 individuals aged 20–40 years from the Copenhagen City Heart Study from 1976 to 1983 until 2001 to 2003 to determine their lung function trajectory; 72 had persistent PRISm trajectory, 76 had normal to PRISm trajectory, 155 had PRISm to normal trajectory, and 857 had normal trajectory. From 2001–2003 until 2018, we determined the risk of cardiopulmonary disease and death. Measurements and Main Results: We recorded 198 admissions for heart disease, 143 for pneumonia, and 64 for chronic obstructive pulmonary disease as well as 171 deaths. Compared with individuals with normal trajectory, hazard ratios for individuals with persistent PRISm trajectory were 1.55 (95% confidence interval, 0.91–2.65) for heart disease admission, 2.86 (1.70–4.83) for pneumonia admission, 6.57 (3.41–12.66) for chronic obstructive pulmonary disease admission, and 3.68 (2.38–5.68) for all-cause mortality. Corresponding hazard ratios for individuals with normal to PRISm trajectory were 1.91 (1.24–2.95), 2.74 (1.70–4.42), 7.61 (4.21–13.72), and 2.96 (1.94–4.51), respectively. Prognosis of individuals with PRISm to normal trajectory did not differ from those with normal trajectory. Conclusions: PRISm in middle-aged individuals is associated with increased risk of cardiopulmonary disease and all-cause mortality, but individuals who recover from PRISm during their adult life are no longer at increased risk.

1 May 2017 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
YÇYunus Çolak
Yunus Çolak
SAShoaib Afzal
Shoaib Afzal
BNBørge G Nordestgaard
Børge G Nordestgaard
JVJørgen Vestbo
Jørgen Vestbo
PLPeter Lange
Peter Lange